Fig. 5: Human thyroid epiCsTPO,CD64t are protected from antibody-mediated killing.
From: Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
a,b, Human thyroid epiCsTPO and epiCsTPO,CD64t were challenged in impedance NK cell ADCC (a) and CDC (b) assays with different concentrations of an anti-TPO IgG1 antibody (mean ± s.d.; three independent replicates per group and timepoint). c–e, Human thyroid epiCsTPO and epiCsTPO,CD64t were incubated with serum from Hashimoto’s patients 1 (c), 2 (d) and 3 (e) in impedance CDC assays (mean ± s.d.; three independent replicates per group and timepoint). ULN, upper limit of normal. f, 5 × 104 human thyroid epiCsTPO or epiCsTPO,CD64t were injected subcutaneously into NSG mice with 106 human NK cells. Both groups received three subcutaneous doses of anti-TPO IgG1 1 mg on days 0, 1 and 2. g,h, BLI signals of thyroid epiCsTPO (g) and epiCsTPO,CD64t (h) were followed (all individual mice were plotted, and BLI pictures of one representative mouse per group are shown). s.c., subcutaneous.
